Cancer Research and Treatment

Hematologic malignancy

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea: Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee; Cancer Res Treat. 2024;56(2):681-687. Published online November 10, 2023; DOI: https://doi.org/10.4143/crt.2023.1042

Purpose
Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials and Methods
Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results
The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.
Conclusion
In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.

Citations

Citations to this article as recorded by

An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma
Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang
Expert Opinion on Biological Therapy.2025; 25(1): 9. CrossRef
Pembrolizumab

Reactions Weekly.2024; 2025(1): 390. CrossRef

3,697 View
210 Download
1 Web of Science
2 Crossref

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study: Joon Young Hur, Youjin Kim, Ghee-Young Kwon, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Su Jin Lee, Se Hoon Park; Cancer Res Treat. 2019;51(4):1269-1274. Published online January 9, 2019; DOI: https://doi.org/10.4143/crt.2018.604

Abstract PDF PubReader ePub

Purpose
Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who failed platinum-based chemotherapy.
Materials and Methods
A retrospective study using the Samsung Medical Center cancer chemotherapy registry was performed on 50 consecutive patients with mUC treated with atezolizumab, regardless of their PD-L1(SP142) status, as salvage therapy after chemotherapy failure between May 2017 and June 2018. Endpoints included overall response rate (RR), progression-free survival (PFS), and safety.
Results
Among 50 patients, men constituted 76% and the median age was 68 years (range, 46 to 82 years). Twenty-three patients (46%) received atezolizumab as second-line therapy. PD-L1 (SP142) status IC0/1 and IC2/3 were found in 21 (42%) and 21 (42%) of patients, respectively; in eight patients (16%), PD-L1 (SP142) expression was not available. Atezolizumab was generally well tolerated, with pruritus and fatigue being the most commonly observed toxicities. As a result, partial response was noted in 20 patients (40%), with 12 (24%) stable diseases. RRwas higherin IC2/3 (62%) than in IC0/1 patients (24%, p=0.013). The median PFS was 7.4 months (95% confidence interval, 3.4 to 11.4 months). As expected, PFS also was significantly longer in IC2/3 patients than in IC0/1 (median, 12.7 vs. 2.1 months; p=0.005). PFS was not significantly influenced by age, sex, performance status, number of previous chemotherapy, site of metastases, or any of the baseline laboratory parameters.
Conclusion
In this retrospective study, atezolizumab demonstrated clinically efficacy and tolerability in unselected mUC patients who failed platinum-based chemotherapy.

Citations

Citations to this article as recorded by

Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer
Rocío Díaz Acedo, Mercedes Galvan Banqueri, Silvia Artacho Criado, Eva María Fernández Parra, Rocío Jiménez Galán, Ana Isabel Gago Sánchez, Juan Francisco Marín Pozo, María José Martínez Bautista
International Journal of Clinical Pharmacy.2024; 46(2): 382. CrossRef
Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Biomedicines.2022; 10(8): 2005. CrossRef
Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options
Inkeun Park, Jae Lyun Lee
The Korean Journal of Internal Medicine.2020; 35(4): 834. CrossRef

7,691 View
283 Download
3 Web of Science
3 Crossref

Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib: Jung Hye Choi, Joon Young Hur, Young-Woong Won; Cancer Res Treat. 2023;55(2):704-705.; DOI: https://doi.org/10.4143/crt.2022.1524

PDF PubReader ePub

Citations

Citations to this article as recorded by

HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs): a Systematic Review and Meta-Analysis
Ahmed Azzam, Heba Khaled, Basem Osama Ashry, Sarah Mohamed Hussein, Manar Osama, Ameer Ahmed, Omar Yousef, Anees Hjazeen, Ahmed A. Allam, Gellan Alaa Mohamed Kamel
Current Infectious Disease Reports.2024; 26(1): 1. CrossRef
Hepatitis B Virus Reactivation with Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review
Arzu Altunçekiç Yıldırım, Celali Kurt, Burcu Ülküden, Yeliz Çetinkol
Viral Hepatitis Journal.2024; 30(1): 19. CrossRef
Chlorambucil/ibrutinib

Reactions Weekly.2023; 1965(1): 147. CrossRef

3,696 View
125 Download
3 Crossref

Search